TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35879039

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 700
Study: 35879127

Group type: EXPERIMENTAL
Intervention: PSMA-RGS
Number of subjects: 18
Study: 35879335

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 12981
Study: 35879678

Group type: EXPERIMENTAL
Intervention: ASSIST 1.0
Number of subjects: 17

Group type: COMPARATOR
Intervention: Regular home care (control)
Number of subjects: 17
Study: 35879765

Group type: EXPERIMENTAL
Intervention: AKI defined by serum creatinine (sCr)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: AKI defined by urine output (UO)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Acute kidney disease (AKD)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Rapid reversal of AKI
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Kidney recovery in surviving AKI patients
Number of subjects: 1286
Study: 35879931

Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (AAV5-hFVIII-SQ) infusion
Number of subjects: 23
Study: 35879962

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 650
Study: 35880164

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) regimen delivering 30 Gy in five planned consecutive daily fractions.
Number of subjects: 23
Study: 35880474

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4805

Group type: COMPARATOR
Intervention: Control (Q1-Q3; NT-proBNP: Q1, ≤1556 pg/mL; Q2, >1556-2816 pg/mL; Q3, >2816-5314 pg/mL)
Number of subjects: 4805
Study: 35880941

Group type: EXPERIMENTAL
Intervention: Adoptive cell therapies
Number of subjects: 0
Study: 35880940

Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy (including tumor-infiltrating lymphocyte therapy, engineered T cell receptor therapy, chimeric antigen receptor therapy, dendritic cell therapy, and natural killer cell therapy)
Number of subjects: 0
Study: 35880942

Group type: EXPERIMENTAL
Intervention: Adoptive cellular therapy (ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Number of subjects: 0
Study: 35880983

Group type: EXPERIMENTAL
Intervention: Hemoglobin quantification on contrast-enhanced photon-counting CT data sets
Number of subjects: 0
Study: 35881009

Group type: EXPERIMENTAL
Intervention: Fesoterodine (Toviaz)
Number of subjects: 6
Study: 35881028

Group type: EXPERIMENTAL
Intervention: 18 mg lenvatinib + everolimus (5 mg daily)
Number of subjects: 343

Group type: COMPARATOR
Intervention: 14 mg lenvatinib + everolimus (5 mg daily)
Number of subjects: 343
Study: 35881109

Group type: EXPERIMENTAL
Intervention: Semistructured patient-centered deprescribing interview
Number of subjects: 177
Study: 35881437

Group type: EXPERIMENTAL
Intervention: Electronic discharge order set (DOS) plus nurse follow-up calls
Number of subjects: 158

Group type: COMPARATOR
Intervention: Enhanced standard care (ESC)
Number of subjects: 158
Study: 35881467

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 13133
Study: 35881826

Group type: EXPERIMENTAL
Intervention: TABCT product
Number of subjects: 29
Study: 35881859

Group type: EXPERIMENTAL
Intervention: Physical activity intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 35881895

Group type: EXPERIMENTAL
Intervention: SP16 (0.2 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Historical placebo-treated group
Number of subjects: 10
Study: 35881967

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactobacillus reuteri
Number of subjects: 0
Study: 35882366

Group type: EXPERIMENTAL
Intervention: Telehealth prenatal care
Number of subjects: 107

Group type: COMPARATOR
Intervention: In-person prenatal care
Number of subjects: 107
Study: 35882382

Group type: EXPERIMENTAL
Intervention: Patients with apparent treatment-resistant hypertension (aTRH)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Patients with aTRH
Number of subjects: 140

Group type: COMPARATOR
Intervention: Patients without aTRH
Number of subjects: 140
Study: 35882447

Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9-mediated knockout of TGF-β receptor 2 in OvCa TIL
Number of subjects: 4
Study: 35882452

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No gestational diabetes mellitus (Control)
Number of subjects: 200
Study: 35882457

Group type: EXPERIMENTAL
Intervention: Higher Charlson comorbidity index (CCI score ≥6)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Each additional CCI comorbidity
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 298

Group type: COMPARATOR
Intervention: Few comorbidities (CCI score 3-5)
Number of subjects: 298
Study: 35882459

Group type: EXPERIMENTAL
Intervention: Changes in PMH care practices during the COVID-19 Pandemic as reported by experts through an online survey.
Number of subjects: 0
Study: 35882475

Group type: EXPERIMENTAL
Intervention: Full-dose EPOCH +/- rituximab
Number of subjects: 69
Study: 35882514

Group type: EXPERIMENTAL
Intervention: Corneal radius of curvature (CR) >7.9 mm
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Fundus tessellation grades
Number of subjects: 1127
Study: 35882728

Group type: EXPERIMENTAL
Intervention: PARPi-FL mouthwash formulation (1,000 nM of PARPi-FL dissolved in 4.5 ml of PEG 300 and 9.5 ml of water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New one-step formulation of PARPi-FL (direct addition of water into a vial containing PARPi-FL and PEG 3350)
Number of subjects: 0
Study: 35882759

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy prior to Lateral Lymph Node Dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35883039

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Remimazolam and Remifentanil
Number of subjects: 38
Study: 35883131

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up and assessment of complications/sequalae
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model analysis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Postoperative complications/sequalae
Number of subjects: 122
Study: 35883167

Group type: EXPERIMENTAL
Intervention: FBT-V
Number of subjects: 23
Study: 35883226

Group type: EXPERIMENTAL
Intervention: Food liking ratings
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Larger portion sizes (100%, 133%, 167%, 200% of baseline amounts)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selected portion of a food on the survey
Number of subjects: 51
Study: 35883236

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free regimens
Number of subjects: 1451

Group type: COMPARATOR
Intervention: Corticosteroid-containing regimens
Number of subjects: 1451
Study: 35883458

Group type: EXPERIMENTAL
Intervention: Th17 gene expression analysis (IL23R, IL17, SGK1, TGFβ, RORγ, FOXO1, RANBP1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th17 markers as diagnostic markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th17 markers as risk factors
Number of subjects: 0
Study: 35883493

Group type: EXPERIMENTAL
Intervention: LPS challenged individuals
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 128
Study: 35884990

Group type: EXPERIMENTAL
Intervention: whole-plant cannabis extract (CBD:THC 20:1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: purified CBD and THC extract (CBD:THC 20:1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 150
Study: 35886510

Group type: EXPERIMENTAL
Intervention: Long-term physical exercise (8 months of training)
Number of subjects: 98
Study: 35887529

Group type: EXPERIMENTAL
Intervention: Panel of biomarkers (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, transferrin, ganglioside-activating protein GM2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of kidney function between smokers and non-smokers
Number of subjects: 0
Study: 35887809

Group type: EXPERIMENTAL
Intervention: Virtual Exercise Program throughout Pregnancy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 192
Study: 35887871

Group type: EXPERIMENTAL
Intervention: Ozonated water irrigator used daily in conjunction with proper home oral hygiene.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group performing only home oral hygiene.
Number of subjects: 0
Study: 35887994

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: SIRS score
Number of subjects: 57
Study: 35891387

Group type: EXPERIMENTAL
Intervention: dsRNA miR-29b-1*
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized miR-29b-1* mimics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrambled short dsRNA sequences
Number of subjects: 0
Study: 35891471

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection or vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of antibody avidity in serological assays
Number of subjects: 0
Study: 35891515

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence testing
Number of subjects: 0
Study: 35891697

Group type: EXPERIMENTAL
Intervention: HRV infection (specifically HRV-A, HRV-B, HRV-C)
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: HRV-C
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: HRV-A
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: HRV-B
Number of subjects: 5662
Study: 35891921

Group type: EXPERIMENTAL
Intervention: Colorectal Bundle (CB) implemented after a 6-month control period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local standard treatment during the 6-month control period
Number of subjects: 0
Study: 35892294

Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 2
Study: 35892341

Group type: EXPERIMENTAL
Intervention: Dostarlimab (JEMPERLI)
Number of subjects: 0
Study: 35893347

Group type: EXPERIMENTAL
Intervention: Scrambler Therapy (ST)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham Scrambler Therapy
Number of subjects: 43
Study: 35893678

Group type: EXPERIMENTAL
Intervention: Torque Teno Virus (TTV) detection
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Genomic analysis of TTV
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Co-infection analysis
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Age correlation analysis
Number of subjects: 816
Study: 35894075

Group type: EXPERIMENTAL
Intervention: Fully automated online behavioral weight-loss intervention
Number of subjects: 721
Study: 35894077

Group type: EXPERIMENTAL
Intervention: Inhibitor of aldose reductase (zopolrestat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic deletion of Akr1b3
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat diet (control)
Number of subjects: 0
Study: 35894609

Group type: EXPERIMENTAL
Intervention: RAASIs only
Number of subjects: 7975

Group type: COMPARATOR
Intervention: Combination of RAASIs and other AHAs
Number of subjects: 7975

Group type: COMPARATOR
Intervention: ACEIs only
Number of subjects: 7975
Study: 35894680

Group type: COMPARATOR
Intervention: Traditional screening
Number of subjects: 21290

Group type: COMPARATOR
Intervention: Criteria-based screening
Number of subjects: 21290

Group type: COMPARATOR
Intervention: Specific referral letter
Number of subjects: 21290

Group type: COMPARATOR
Intervention: Screening supplemented with motivation
Number of subjects: 21290

Group type: COMPARATOR
Intervention: Referral to a specific dental treatment facility
Number of subjects: 21290

Group type: COMPARATOR
Intervention: Post-screening referral letter based on common-sense model
Number of subjects: 21290
Study: 35894729

Group type: EXPERIMENTAL
Intervention: Oral Ibuprofen 10 mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral Paracetamol 10 mg/kg
Number of subjects: 44
Study: 35894761

Group type: EXPERIMENTAL
Intervention: Dental implant treatment (four implants inserted bilaterally in the maxilla)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Peri-implantitis operation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dental implant treatment in patients on high-dose antiresorptive medication (HDAR)
Number of subjects: 1
Study: 35895056

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/d for 12 weeks)
Number of subjects: 40
Study: 35895880

Group type: EXPERIMENTAL
Intervention: COVID-19 period
Number of subjects: 1338

Group type: COMPARATOR
Intervention: Meningococcal conjugate ACWY vaccination
Number of subjects: 1338
Study: 35896204

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35896216

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks during maintenance phase
Number of subjects: 598
Study: 35897011

Group type: EXPERIMENTAL
Intervention: Adropin, adiponectin, total testosterone, and lipid profile parameters measured in obese men
Number of subjects: 43

Group type: COMPARATOR
Intervention: Adropin, adiponectin, total testosterone, and lipid profile parameters measured in normal-weight men
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Correlation analysis of adropin, adiponectin, and total testosterone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adropin as a predictor risk factor for testosterone
Number of subjects: 43
Study: 35897070

Group type: EXPERIMENTAL
Intervention: Probabilistic unsupervised clustering model
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Cluster labels added to the IMPACT extended model
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Cluster with 'moderate' TBI and deranged metabolic profile
Number of subjects: 1728
Study: 35897078

Group type: EXPERIMENTAL
Intervention: Visually tau-positive scans
Number of subjects: 0
Study: 35897111

Group type: EXPERIMENTAL
Intervention: I-COPE intervention including patient-reported data, clinical decision support tools, and shared decision-making tools.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Project ECHO® training for primary care providers.
Number of subjects: 35
Study: 35897478

Group type: EXPERIMENTAL
Intervention: First lockdown
Number of subjects: 8121

Group type: EXPERIMENTAL
Intervention: Second lockdown
Number of subjects: 8121

Group type: EXPERIMENTAL
Intervention: After second lockdown
Number of subjects: 8121

Group type: COMPARATOR
Intervention: Pre-pandemic period
Number of subjects: 8121
Study: 35898141

Group type: EXPERIMENTAL
Intervention: Protein-calorie supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35898313

Group type: EXPERIMENTAL
Intervention: Home gardens intervention
Number of subjects: 310
Study: 35898343

Group type: COMPARATOR
Intervention: Prototype (mRNA-1273)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.1+Beta (1 or 2 doses)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.1+Delta
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.1 monovalent
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.1+Prototype
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.1
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Omicron BA.4/BA.5
Number of subjects: 597
Study: 35898518

Group type: EXPERIMENTAL
Intervention: Latanoprost BAK-free
Number of subjects: 161

Group type: COMPARATOR
Intervention: Reference (Latanoprost with BAK)
Number of subjects: 161
Study: 35898703

Group type: EXPERIMENTAL
Intervention: Autologous DC-based vaccine (DCVAC)
Number of subjects: 1000
Study: 35899095

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 1
Study: 35899212

Group type: EXPERIMENTAL
Intervention: AIDA International Registry for VEXAS syndrome
Number of subjects: 0
Study: 35899271

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Donepezil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Donepezil alone
Number of subjects: 44
Study: 35899469

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 35899784

Group type: EXPERIMENTAL
Intervention: COACH (Community Outreach teleheAlth program)
Number of subjects: 75
Study: 35900079

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy
Number of subjects: 0
Study: 35900614

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI) using standardised MY-RADS protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised WB-MRI protocols
Number of subjects: 0
Study: 35900694

Group type: EXPERIMENTAL
Intervention: Zanubrutinib monotherapy
Number of subjects: 211
Study: 35900699

Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin + Bendamustine + Rituximab (Pola+BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine + Rituximab (BR)
Number of subjects: 0
Study: 35900808

Group type: EXPERIMENTAL
Intervention: PuzzleWalk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Google Fit
Number of subjects: 24
Study: 35900824

Group type: EXPERIMENTAL
Intervention: Posts generated by interventionists
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Posts that directly mentioned weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Posts that directly mentioned goals
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Replies from other participants
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Replies from interventionists
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sentiment of the conversation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Previous engagement in posts
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Machine learning classification
Number of subjects: 80
Study: 35900835

Group type: EXPERIMENTAL
Intervention: Smiling Instead of Smoking app (version 2)
Number of subjects: 100
Study: 35901014

Group type: EXPERIMENTAL
Intervention: Patients aged 60 years or older
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients aged 40-59 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients aged 18-39 years
Number of subjects: 0
Study: 35901272

Group type: EXPERIMENTAL
Intervention: Low- and no-calorie sweetened beverages (LNCSB)
Number of subjects: 416830

Group type: EXPERIMENTAL
Intervention: Substitution of LNCSB for sugar-sweetened beverages (SSB)
Number of subjects: 416830

Group type: EXPERIMENTAL
Intervention: Substitution of water for SSB
Number of subjects: 416830
Study: 35901423

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 35901693

Group type: EXPERIMENTAL
Intervention: LCTOPC1 (2 × 106, 1 × 107, or 2 × 107 cells) administered via intraparenchymal injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LCTOPC1
Number of subjects: 25
Study: 35901717

Group type: EXPERIMENTAL
Intervention: Intervention (60 cases: 21 microsurgery, 19 embolization, 20 hybrid surgery)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Microsurgery and hybrid surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hybrid surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conservative management (22 cases)
Number of subjects: 82
Study: 35901755

Group type: EXPERIMENTAL
Intervention: Target Ultra and Nano coils
Number of subjects: 100
Study: 35901765

Group type: EXPERIMENTAL
Intervention: Framingham Risk Score (FRS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Systematic Coronary Risk Evaluation-Older Persons (SCORE-OP)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Kiefer's Comorbidity Index (KCI)
Number of subjects: 140
Study: 35902154

Group type: EXPERIMENTAL
Intervention: Dental hygienists
Number of subjects: 8902

Group type: EXPERIMENTAL
Intervention: Dentists
Number of subjects: 8902

Group type: COMPARATOR
Intervention: Unvaccinated but planning on getting vaccinated
Number of subjects: 8902

Group type: EXPERIMENTAL
Intervention: Vaccinated respondents
Number of subjects: 8902
Study: 35902169

Group type: EXPERIMENTAL
Intervention: Watchman device implantation with PDL≤5 at 1 year
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Watchman device implantation without PDL≤5 at 1 year
Number of subjects: 1054
Study: 35902229

Group type: EXPERIMENTAL
Intervention: Ruptured aneurysm coiling
Number of subjects: 16247

Group type: COMPARATOR
Intervention: Ruptured aneurysm clipping
Number of subjects: 16247

Group type: COMPARATOR
Intervention: aSAH in-hospital mortality
Number of subjects: 16247

Group type: COMPARATOR
Intervention: aSAH admissions
Number of subjects: 16247

Group type: COMPARATOR
Intervention: Mild aSAH presentations
Number of subjects: 16247

Group type: COMPARATOR
Intervention: Moderate aSAH presentations
Number of subjects: 16247

Group type: COMPARATOR
Intervention: Higher severity aSAH presentations
Number of subjects: 16247
Study: 35902389

Group type: EXPERIMENTAL
Intervention: Younger infants (<3 months)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Older infants (≥6 months)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: RSV-A and RSV-B
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Infants with severe RSV infection (higher ReSViNET score, fever, hospitalization, intensive care)
Number of subjects: 325
Study: 35902419

Group type: EXPERIMENTAL
Intervention: 2019 ESC classification
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: 2021 ESC classification
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: ASCVD + TOD
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: ASCVD only
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: ≥ 3 additional ASCVD risk factors
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Presence of TOD
Number of subjects: 15773
Study: 35902798

Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (radiotherapy: 45 Gy/25 f and concurrent chemotherapy: S-1: 40-60 mg twice a day, followed by six cycles of consolidated chemotherapy (SOX: S-1 and oxaliplatin) and surgery
Number of subjects: 0
Study: 35902809

Group type: EXPERIMENTAL
Intervention: Behavioral weight management program (MOVE UP), 13-month duration
Number of subjects: 29
Study: 35902867

Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7 (TXA-127)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35903159

Group type: EXPERIMENTAL
Intervention: Attachment Story Completion Task scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal attachment and mental health
Number of subjects: 0